This is my first time at the American Society of Clinical Oncology meeting. I knew it was the premiere oncology meeting in the world, but I am pleased to see and experience the level of scientific progress and collaboration on display.
ASCO's theme this year is personalized medicine, which is fitting given GSK's approach to the future of treatment. It's clear that we need to provide more treatment options to patients with cancer.
In the last 55 years in the
It's important for us to be at ASCO. GSK is committed to this community and to ensuring that all stakeholders, physicians, nurses and patient groups have the tools they need to bring the right medicine to the right patient. And we also know it's our job that to make sure patients have access to those medicines--what's the point of developing great medicines if patients can't get them?
This past year has been an interesting one both for cancer research and awareness. There has been a lot of media coverage of a few high-profile celebrities going through cancer treatment, and the Stand Up to Cancer initiative has mobilized different groups to tackle this disease head-on. We're all focused on the same thing: finding the best ways to fight this disease--and win.